Switch theme
Sign up to access all valuation multiples
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
2015
2.6K+
LTM Revenue $789M
LTM EBITDA -$167M
$4.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Legend Biotech has a last 12-month revenue (LTM) of $789M and a last 12-month EBITDA of -$167M.
In the most recent fiscal year, Legend Biotech achieved revenue of $627M and an EBITDA of -$113M.
Legend Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Legend Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $789M | XXX | $627M | XXX | XXX | XXX |
| Gross Profit | $503M | XXX | $393M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | -$167M | XXX | -$113M | XXX | XXX | XXX |
| EBITDA Margin | -21% | XXX | -18% | XXX | XXX | XXX |
| EBIT | -$235M | XXX | -$303M | XXX | XXX | XXX |
| EBIT Margin | -30% | XXX | -48% | XXX | XXX | XXX |
| Net Profit | -$162M | XXX | -$177M | XXX | XXX | XXX |
| Net Margin | -21% | XXX | -28% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $14.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Legend Biotech's stock price is $29.
Legend Biotech has current market cap of $5.3B, and EV of $4.7B.
See Legend Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.7B | $5.3B | XXX | XXX | XXX | XXX | $-0.45 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Legend Biotech has market cap of $5.3B and EV of $4.7B.
Legend Biotech's trades at 7.5x EV/Revenue multiple, and -41.4x EV/EBITDA.
Equity research analysts estimate Legend Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Legend Biotech has a P/E ratio of -32.8x.
See valuation multiples for Legend Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.3B | XXX | $5.3B | XXX | XXX | XXX |
| EV (current) | $4.7B | XXX | $4.7B | XXX | XXX | XXX |
| EV/Revenue | 5.9x | XXX | 7.5x | XXX | XXX | XXX |
| EV/EBITDA | -28.0x | XXX | -41.4x | XXX | XXX | XXX |
| EV/EBIT | -20.0x | XXX | -15.4x | XXX | XXX | XXX |
| EV/Gross Profit | 9.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -32.8x | XXX | -30.1x | XXX | XXX | XXX |
| EV/FCF | -22.3x | XXX | -29.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLegend Biotech's last 12 month revenue growth is 58%
Legend Biotech's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Legend Biotech's rule of 40 is -110% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Legend Biotech's rule of X is 123% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Legend Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 58% | XXX | 58% | XXX | XXX | XXX |
| EBITDA Margin | -21% | XXX | -18% | XXX | XXX | XXX |
| EBITDA Growth | -107% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -110% | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 123% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 66% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 111% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Legend Biotech acquired XXX companies to date.
Last acquisition by Legend Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Legend Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Legend Biotech founded? | Legend Biotech was founded in 2015. |
| Where is Legend Biotech headquartered? | Legend Biotech is headquartered in United States of America. |
| How many employees does Legend Biotech have? | As of today, Legend Biotech has 2.6K+ employees. |
| Who is the CEO of Legend Biotech? | Legend Biotech's CEO is Dr. Ying Huang, PhD. |
| Is Legend Biotech publicy listed? | Yes, Legend Biotech is a public company listed on NAS. |
| What is the stock symbol of Legend Biotech? | Legend Biotech trades under LEGN ticker. |
| When did Legend Biotech go public? | Legend Biotech went public in 2020. |
| Who are competitors of Legend Biotech? | Similar companies to Legend Biotech include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Legend Biotech? | Legend Biotech's current market cap is $5.3B |
| What is the current revenue of Legend Biotech? | Legend Biotech's last 12 months revenue is $789M. |
| What is the current revenue growth of Legend Biotech? | Legend Biotech revenue growth (NTM/LTM) is 58%. |
| What is the current EV/Revenue multiple of Legend Biotech? | Current revenue multiple of Legend Biotech is 5.9x. |
| Is Legend Biotech profitable? | Yes, Legend Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Legend Biotech? | Legend Biotech's last 12 months EBITDA is -$167M. |
| What is Legend Biotech's EBITDA margin? | Legend Biotech's last 12 months EBITDA margin is -21%. |
| What is the current EV/EBITDA multiple of Legend Biotech? | Current EBITDA multiple of Legend Biotech is -28.0x. |
| What is the current FCF of Legend Biotech? | Legend Biotech's last 12 months FCF is -$210M. |
| What is Legend Biotech's FCF margin? | Legend Biotech's last 12 months FCF margin is -27%. |
| What is the current EV/FCF multiple of Legend Biotech? | Current FCF multiple of Legend Biotech is -22.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
